HC Wainwright Forecasts Lower Earnings for Biomea Fusion

Biomea Fusion, Inc. (NASDAQ:BMEA) – Equities research analysts at HC Wainwright lowered their FY2025 earnings per share (EPS) estimates for shares of Biomea Fusion in a research note issued to investors on Tuesday, April 1st. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($3.91) for the year, down from their prior forecast of ($3.17). HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Biomea Fusion’s current full-year earnings is ($3.93) per share. HC Wainwright also issued estimates for Biomea Fusion’s FY2026 earnings at ($3.56) EPS, FY2027 earnings at ($2.39) EPS and FY2028 earnings at ($2.45) EPS.

Biomea Fusion (NASDAQ:BMEA) last issued its quarterly earnings results on Monday, March 31st. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.19.

BMEA has been the topic of a number of other reports. Oppenheimer set a $10.00 price target on Biomea Fusion in a research note on Monday, March 24th. Barclays cut their target price on Biomea Fusion from $11.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Wednesday. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $16.00 price target on shares of Biomea Fusion in a report on Wednesday, March 19th. Two research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $23.91.

Biomea Fusion Trading Up 8.7 %

Shares of BMEA opened at $2.12 on Thursday. The firm has a market capitalization of $76.83 million, a price-to-earnings ratio of -0.53 and a beta of -0.26. The firm’s fifty day simple moving average is $3.10 and its 200-day simple moving average is $5.82. Biomea Fusion has a twelve month low of $1.86 and a twelve month high of $13.66.

Hedge Funds Weigh In On Biomea Fusion

A number of hedge funds and other institutional investors have recently made changes to their positions in BMEA. Bayesian Capital Management LP acquired a new stake in Biomea Fusion during the 4th quarter worth approximately $42,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Biomea Fusion during the third quarter worth approximately $111,000. Wells Fargo & Company MN grew its position in Biomea Fusion by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 12,914 shares of the company’s stock valued at $50,000 after buying an additional 4,399 shares during the last quarter. Intech Investment Management LLC acquired a new position in Biomea Fusion in the 4th quarter valued at $54,000. Finally, Maia Wealth LLC acquired a new position in Biomea Fusion in the 4th quarter valued at $62,000. Hedge funds and other institutional investors own 96.72% of the company’s stock.

Biomea Fusion Company Profile

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.